NO20002831L - Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette - Google Patents

Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette

Info

Publication number
NO20002831L
NO20002831L NO20002831A NO20002831A NO20002831L NO 20002831 L NO20002831 L NO 20002831L NO 20002831 A NO20002831 A NO 20002831A NO 20002831 A NO20002831 A NO 20002831A NO 20002831 L NO20002831 L NO 20002831L
Authority
NO
Norway
Prior art keywords
drug
soft pellet
soft
preparing
methods
Prior art date
Application number
NO20002831A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002831D0 (no
Inventor
Hiromitsu Yoshida
Hideki Ito
Yasuko Soeda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20002831D0 publication Critical patent/NO20002831D0/no
Publication of NO20002831L publication Critical patent/NO20002831L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20002831A 1997-12-03 2000-06-02 Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette NO20002831L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33322897 1997-12-03
PCT/JP1998/005159 WO1999027911A1 (fr) 1997-12-03 1998-11-16 Medicament en pastilles souples et procede de fabrication

Publications (2)

Publication Number Publication Date
NO20002831D0 NO20002831D0 (no) 2000-06-02
NO20002831L true NO20002831L (no) 2000-08-03

Family

ID=18263764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002831A NO20002831L (no) 1997-12-03 2000-06-02 Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette

Country Status (16)

Country Link
EP (1) EP1036562A1 (de)
KR (1) KR20010032303A (de)
CN (1) CN1283991A (de)
AR (1) AR015491A1 (de)
AU (1) AU1054399A (de)
BR (1) BR9815345A (de)
CA (1) CA2310826A1 (de)
HU (1) HUP0004821A2 (de)
ID (1) ID28057A (de)
IL (1) IL136251A0 (de)
NO (1) NO20002831L (de)
NZ (1) NZ504711A (de)
PL (1) PL340736A1 (de)
TR (1) TR200001596T2 (de)
WO (1) WO1999027911A1 (de)
ZA (1) ZA9810882B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1417958A1 (de) * 2002-11-08 2004-05-12 Pari GmbH Feuchtgranulierungsverfahren
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005004875A1 (ja) * 2003-07-14 2005-01-20 Sankyo Company, Limited 経肺投与用医薬組成物
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2124898B1 (de) * 2007-01-10 2013-08-14 Board of Regents, The University of Texas System Verstärkte freisetzung immunsuppressiver arzneizusammensetzungen zur pulmonalen verabreichung
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
CN101969959A (zh) 2007-07-31 2011-02-09 利默里克生物制药公司 磷酸化吡喃酮类似物和方法
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5872564B2 (ja) 2011-09-14 2016-03-01 塩野義製薬株式会社 吸入用医薬組成物
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
JP2736168B2 (ja) * 1992-03-10 1998-04-02 フアイソンズ・ピーエルシー 医薬製剤
AU4066693A (en) * 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
JPH08291072A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法

Also Published As

Publication number Publication date
NO20002831D0 (no) 2000-06-02
KR20010032303A (ko) 2001-04-16
ID28057A (id) 2001-05-03
AR015491A1 (es) 2001-05-02
CN1283991A (zh) 2001-02-14
WO1999027911A1 (fr) 1999-06-10
IL136251A0 (en) 2001-05-20
PL340736A1 (en) 2001-02-26
AU1054399A (en) 1999-06-16
BR9815345A (pt) 2000-11-21
EP1036562A1 (de) 2000-09-20
TR200001596T2 (tr) 2000-12-21
NZ504711A (en) 2002-02-01
HUP0004821A2 (hu) 2001-06-28
ZA9810882B (en) 1999-05-26
CA2310826A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
NO20002831L (no) Medikament i myk pelletform og fremgangsmÕter for fremstilling av dette
AU692550B2 (en) Fluoxetine pharmaceutical formulations
CA2277913A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
NZ535284A (en) Microparticles of glycopyrrolate for the treatment of respiratory diseases
MY115688A (en) Pharmaceutical composition for administration by inhalation
AU1537095A (en) Therapeutic agents containing thyroid hormones
PL334493A1 (en) Novel inhalable preparation of 0.28 to 0.38 g/ml bulk density containing budesonide
PL334528A1 (en) Novel inhalable preparation of 0.28 to 0.38 g/ml bulk density containing formotherol
KR880004805A (ko) 분무건조된 아세트아미노펜
NO20054897L (no) Farmasoytisk preparat inneholdende platinakompleks som aktiv substans og fremgangsmate for fremstilling derav
NZ236631A (en) Process for the preparation of a spray dried powdered pharmaceutical formulation of naproxen
EE9900293A (et) Uus inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, selle valmistamise protsess ja kasutamine
DK165438B (da) Tabletter indeholdende en hurtig dispergerbar kerne
JP4891081B2 (ja) ツタの葉抽出物の製造方法および該方法により製造される抽出物
ES2184561A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
WO2001070172A3 (es) Forma farmaceutica solida de administracion oral dispersable en agua que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica
CN1050052C (zh) 戒烟穴贴膏
CN108272904A (zh) 一种后遗影响低的麻醉用植物提取物及其制造方法
CN106798732A (zh) 一种头孢克肟分散片及制备方法
KR880012206A (ko) 구강질환 치료 조성물

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application